SecBot SecBot

IFRX

InflaRx N.V.
Nasdaq· Pharmaceutical Preparations· Inc. P7· CIK 0001708688 Biotech & Drug Discovery
$1.60 +0.04 (+2.24%)
Oct 26 4:00 PM ET · prev $1.56
Market cap
$225.5M
Micro cap
Consensus
Buy
87% Buy or better · 15 analysts
Median target
🔒 Subscribers only
Next earnings
Nov 9
in 14 days · EPS est. −$0.05
1 year
−3.9%
from $1.66 · Oct 27
30 days
−12.4%
from $1.82
52-week range
$0.8250–2.74
−42% from high · low Feb 5
Avg volume 20D
718.9K
Oct 19 spike 2.80M
Short interest
12.36M
≈8.4% of shares · +2.1%
Days to cover
26.6
at average volume
New fund stakes
1
Q2 2026 13F · 0 exits
Filing reports
11
analyzed by SecBot
SecBot read MIXED 7 reports · 90 days
Balance 2 bearish · 0 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 6/7 ·Next Earnings date, Nov 9, 2026
Strongest NEUTRAL InflaRx presented pre-clinical data on izicopan at Kidney Week 2026, showing statistically significant renal…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsBULLISH

    Q2 2026: 8 added (1 new), 2 trimmed or exited. Largest new: Fmr $18.3M.

  • AnalystsBULLISH

    13 of 15 rate it Buy or better.

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.052 → −$0.052 over 90 days. 3 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest +2.1% to 12.36M shares. 26.6 days to cover, ≈8.4% of shares.

  • TrendDOWNTREND

    16% below its 50-day average.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$18.3M
in new stakes
FundMoveSharesValue
FMR LLCNEW8,163,341$18.3M
MARSHALL WACE, LLPADD711,296$1.6M
Squarepoint Ops LLCTRIM179,613$402.3K
HRT FINANCIAL LPDOUBLED143,210$320.0K
CITADEL ADVISORS LLCDOUBLED139,290$312.0K
BNP PARIBAS FINANCIAL MARKETSDOUBLED131,838$295.3K
UBS Group AGDOUBLED79,133$177.3K
SUSQUEHANNA INTERNATIONAL GROUP, LLPTRIM42,784$95.8K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

15 analysts
Buy 87% rate it Buy or better
Strong Buy5Buy8Hold2Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Sep 14, 2026Needham
INITIATE
INITIATEBuy
Aug 7, 2026Cantor Fitzgerald
MAINTAIN
MAINTAINOverweight
May 13, 2026Raymond James
UPGRADE
UPGRADEStrong Buy
May 11, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
May 11, 2026Cantor Fitzgerald
MAINTAIN
MAINTAINOverweight

Earnings setup

Estimates
Nov 9
reports in 14 days
−$0.05
EPS estimate, this quarter
0%
estimate change, 90 days
3↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.05-$0.08–-$0.03-1.0%$0.00
Next Q-$0.06-$0.08–-$0.04-1.9%$0.00
Current FY-$0.27-$0.30–-$0.24-1.5%$0.00
Next FY-$0.37-$0.48–-$0.26-6.2%$0.00
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 9, 2026
Earnings date
IFRX Q3 2026 Earnings Scheduled — 2026-11-09
Recent
Oct 22, 2026
Announcement
InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026
Data from pre-clinical renal disease models demonstrate potential of izicopan for kidney protectionStructural modeling provides new insight into…
Oct 2, 2026
Announcement
InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
Jena, Germany, Oct. 02, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics…
Oct 1, 2026
Announcement
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development
Jena, Germany, Oct. 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics…
Sep 21, 2026
Press release
InflaRx to Host Virtual Capital Markets Day
Jena, Germany, Sept. 21, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics…
Aug 31, 2026
Short interest
Short Interest: IFRX up 30% to 12.3M shares
Settlement 2026-08-31 | Days to cover: 12.01 | ≈8.35% of shares outstanding (est.)

Short side

FINRA· Sep 30, 2026
12,358,339
shares short
+2.1%
vs prior settlement
26.6
days to cover
≈8.4%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 SEC
InflaRx presented pre-clinical data on izicopan at Kidney Week 2026, showing statistically significant renal…
6-K — Impact 3/10
Oct 22, 2026 Press
InflaRx presented pre-clinical data at Kidney Week 2026 showing izicopan reduced renal injury markers in two hamster…
Impact 3/10
Oct 22, 2026 Announcement
InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026
Data from pre-clinical renal disease models demonstrate potential of izicopan for kidney protectionS
Oct 2, 2026 Press
InflaRx announced that its oral C5aR1 antagonist izicopan was selected for a late-breaking poster at ASN Kidney Week…
Impact 3/10
Aug 14, 2026 SEC
InflaRx N.V. filed a 424B5 prospectus supplement to register up to $65 million in ordinary shares for an at-the-market…
424B5 — Impact 5/10
Aug 13, 2026 SEC
InflaRx N.V.'s shelf registration statement (F-3, File No. 333-298039) became effective on August 12, 2026, allowing…
EFFECT — Impact 5/10
Jun 30, 2026 Inst.
FMR LLC — NEW
8,163,341 shares ($18.3M)
Jun 30, 2026 Inst.
MARSHALL WACE, LLP — ADD
711,296 shares ($1.6M)

SecBot reports

11 filings · 10 press releases · 2 bullish · 3 bearish · 6 neutral
All IFRX filing & press-release reports (21)